Optison is an ultrasound contrast agent available in a ready-to-use formulation, providing the benefits of fast preparation time, ease of use, portability, and flexible dosing. 2 The recommended dose ...

Expanding the approval to pediatric patients is expected to improve the diagnostic accuracy of echocardiograms. The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A ...

PRINCETON, NJ ─ November 18, 2013 ─ GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ ...

PRINCETON, NJ, June 13, 2011 – Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison™ (Perflutren Protein-Type A Microspheres ...

GE Healthcare Medical Diagnostics announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in ...

The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients Optison is the only polyethylene glycol (PEG)-free ultrasound ...

Optison is an ultrasound contrast agent available in a ready-to-use formulation, providing the benefits of fast preparation time, ease of use, portability, and flexible dosing. 2 The recommended dose ...

June 15, 2011 (Montreal, Quebec City) — Injection of a diagnostic echo-contrast agent in patients undergoing right heart catheterization did not alter baseline pulmonary pressures from baseline levels ...

GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres ...